FDA safety review to hold up Moderna’s Covid-19 vaccine for teens until 2022
Moderna has run into a delay in its push to extend the reach of its Covid-19 vaccine.
The FDA needs additional time to complete its assessment of Moderna’s emergency use authorization filing for the use of mRNA-1273 among adolescents 12 to 17 years old because the agency wants to “evaluate recent international analyses of the risk of myocarditis after vaccination,” Moderna said. The review could take until January 2022.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 147,700+ biopharma pros reading Endpoints daily — and it's free.